Document is current
Any future updates will be listed below
-
Authors
Kreutzer, Fabian Philipp https://orcid.org/0000-0002-7814-9994
Meinecke, Anna
Mitzka, Saskia
Hunkler, Hannah Jill
Hobuß, Lisa
Abbas, Naisam
Geffers, Robert
Weusthoff, Jan
Xiao, Ke
Jonigk, Danny David
Fiedler, Jan
Thum, Thomas https://orcid.org/0000-0003-4360-1511
-
Funding
Funding for this research was provided by:
fp7 ideas: european research council (Fibrotarget)
horizon 2020 framework programme (Cardioregenix)
deutsche forschungsgemeinschaft (TRR267)
Deutsche Forschungsgemeinschaft (SFB1470)
Medizinische Hochschule Hannover (MHH)
- License Information
-
More Information
Article History
Received: 6 July 2021
Revised: 8 February 2022
Accepted: 9 February 2022
First Online: 2 March 2022
Declarations
:
: T.T. and J.F. filed several patents about noncoding RNAs and/or therapeutic use of natural compounds in fibrosi (outside the field of this manuscript)s. T.T. is founder and shareholder of Cardior Pharmaceuticals (outside the field of this manuscript). The remaining authors declare no competing interest.
